Brian Lian founded publicly traded Viking Therapeutics to focus on metabolic diseases. With obesity drugs in development and the GLP-1 space booming, it’s now a prime M&A target for giants jostling for their share of a potential $100 billion market.Brian Lian had been working as a Wall Street analyst for nearly a decade when he […]
